Global Gram-positive Bacterial Infections Market Research Report 2023

Gram-positive Bacterial Infections Market

The global Gram-positive Bacterial Infections market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Gram-positive Bacterial Infections is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Gram-positive Bacterial Infections is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The global market for Gram-positive Bacterial Infections in Hospital is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global companies of Gram-positive Bacterial Infections include GlaxoSmithKline, Johnson & Johnson Inc., Merck & Co. Inc., Pfizer Inc., AstraZeneca, Astellas Pharma Inc., Novartis AG, Sanofi SA and Sun Pharmaceutical Industries Ltd., etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gram-positive Bacterial Infections, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gram-positive Bacterial Infections.

The Gram-positive Bacterial Infections market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Gram-positive Bacterial Infections market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gram-positive Bacterial Infections companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Gram-positive Bacterial Infections Market Report

Core Chapters

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Gram-positive Bacterial Infections Market Size Growth Rate by Type: 2018 VS 2022 VS 2029

1.2.2 B-Lactam Antimicrobials

1.2.3 Fluoroquinolones

1.2.4 Penicillin

1.2.5 Cephalosporins

1.2.6 RNA Immunoprecipitation (RIP)

1.2.7 Vaccine

1.2.8 Other

1.3 Market by Application

1.3.1 Global Gram-positive Bacterial Infections Market Growth by Application: 2018 VS 2022 VS 2029

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Other

1.4 Study Objectives

1.5 Years Considered

1.6 Years Considered

2.1 Global Gram-positive Bacterial Infections Market Perspective (2018-2029)

2.2 Gram-positive Bacterial Infections Growth Trends by Region

2.2.1 Global Gram-positive Bacterial Infections Market Size by Region: 2018 VS 2022 VS 2029

2.2.2 Gram-positive Bacterial Infections Historic Market Size by Region (2018-2023)

2.2.3 Gram-positive Bacterial Infections Forecasted Market Size by Region (2024-2029)

2.3 Gram-positive Bacterial Infections Market Dynamics

2.3.1 Gram-positive Bacterial Infections Industry Trends

2.3.2 Gram-positive Bacterial Infections Market Drivers

2.3.3 Gram-positive Bacterial Infections Market Challenges

2.3.4 Gram-positive Bacterial Infections Market Restraints

3.1 Global Top Gram-positive Bacterial Infections Players by Revenue

3.1.1 Global Top Gram-positive Bacterial Infections Players by Revenue (2018-2023)

3.1.2 Global Gram-positive Bacterial Infections Revenue Market Share by Players (2018-2023)

3.2 Global Gram-positive Bacterial Infections Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Gram-positive Bacterial Infections Revenue

3.4 Global Gram-positive Bacterial Infections Market Concentration Ratio

3.4.1 Global Gram-positive Bacterial Infections Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Gram-positive Bacterial Infections Revenue in 2022

3.5 Gram-positive Bacterial Infections Key Players Head office and Area Served

3.6 Key Players Gram-positive Bacterial Infections Product Solution and Service

3.7 Date of Enter into Gram-positive Bacterial Infections Market

3.8 Mergers & Acquisitions, Expansion Plans

4.1 Global Gram-positive Bacterial Infections Historic Market Size by Type (2018-2023)

4.2 Global Gram-positive Bacterial Infections Forecasted Market Size by Type (2024-2029)

5.1 Global Gram-positive Bacterial Infections Historic Market Size by Application (2018-2023)

5.2 Global Gram-positive Bacterial Infections Forecasted Market Size by Application (2024-2029)

6.1 North America Gram-positive Bacterial Infections Market Size (2018-2029)

6.2 North America Gram-positive Bacterial Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029

6.3 North America Gram-positive Bacterial Infections Market Size by Country (2018-2023)

6.4 North America Gram-positive Bacterial Infections Market Size by Country (2024-2029)

6.5 United States

6.6 Canada

7.1 Europe Gram-positive Bacterial Infections Market Size (2018-2029)

7.2 Europe Gram-positive Bacterial Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029

7.3 Europe Gram-positive Bacterial Infections Market Size by Country (2018-2023)

7.4 Europe Gram-positive Bacterial Infections Market Size by Country (2024-2029)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8.1 Asia-Pacific Gram-positive Bacterial Infections Market Size (2018-2029)

8.2 Asia-Pacific Gram-positive Bacterial Infections Market Growth Rate by Region: 2018 VS 2022 VS 2029

8.3 Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2018-2023)

8.4 Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2024-2029)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9.1 Latin America Gram-positive Bacterial Infections Market Size (2018-2029)

9.2 Latin America Gram-positive Bacterial Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029

9.3 Latin America Gram-positive Bacterial Infections Market Size by Country (2018-2023)

9.4 Latin America Gram-positive Bacterial Infections Market Size by Country (2024-2029)

9.5 Mexico

9.6 Brazil

10.1 Middle East & Africa Gram-positive Bacterial Infections Market Size (2018-2029)

10.2 Middle East & Africa Gram-positive Bacterial Infections Market Growth Rate by Country: 2018 VS 2022 VS 2029

10.3 Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2018-2023)

10.4 Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2024-2029)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11.1 GlaxoSmithKline

11.1.1 GlaxoSmithKline Company Detail

11.1.2 GlaxoSmithKline Business Overview

11.1.3 GlaxoSmithKline Gram-positive Bacterial Infections Introduction

11.1.4 GlaxoSmithKline Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.1.5 GlaxoSmithKline Recent Development

11.2 Johnson & Johnson Inc.

11.2.1 Johnson & Johnson Inc. Company Detail

11.2.2 Johnson & Johnson Inc. Business Overview

11.2.3 Johnson & Johnson Inc. Gram-positive Bacterial Infections Introduction

11.2.4 Johnson & Johnson Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.2.5 Johnson & Johnson Inc. Recent Development

11.3 Merck & Co. Inc.

11.3.1 Merck & Co. Inc. Company Detail

11.3.2 Merck & Co. Inc. Business Overview

11.3.3 Merck & Co. Inc. Gram-positive Bacterial Infections Introduction

11.3.4 Merck & Co. Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.3.5 Merck & Co. Inc. Recent Development

11.4 Pfizer Inc.

11.4.1 Pfizer Inc. Company Detail

11.4.2 Pfizer Inc. Business Overview

11.4.3 Pfizer Inc. Gram-positive Bacterial Infections Introduction

11.4.4 Pfizer Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.4.5 Pfizer Inc. Recent Development

11.5 AstraZeneca

11.5.1 AstraZeneca Company Detail

11.5.2 AstraZeneca Business Overview

11.5.3 AstraZeneca Gram-positive Bacterial Infections Introduction

11.5.4 AstraZeneca Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.5.5 AstraZeneca Recent Development

11.6 Astellas Pharma Inc.

11.6.1 Astellas Pharma Inc. Company Detail

11.6.2 Astellas Pharma Inc. Business Overview

11.6.3 Astellas Pharma Inc. Gram-positive Bacterial Infections Introduction

11.6.4 Astellas Pharma Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.6.5 Astellas Pharma Inc. Recent Development

11.7 Novartis AG

11.7.1 Novartis AG Company Detail

11.7.2 Novartis AG Business Overview

11.7.3 Novartis AG Gram-positive Bacterial Infections Introduction

11.7.4 Novartis AG Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.7.5 Novartis AG Recent Development

11.8 Sanofi SA

11.8.1 Sanofi SA Company Detail

11.8.2 Sanofi SA Business Overview

11.8.3 Sanofi SA Gram-positive Bacterial Infections Introduction

11.8.4 Sanofi SA Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.8.5 Sanofi SA Recent Development

11.9 Sun Pharmaceutical Industries Ltd.

11.9.1 Sun Pharmaceutical Industries Ltd. Company Detail

11.9.2 Sun Pharmaceutical Industries Ltd. Business Overview

11.9.3 Sun Pharmaceutical Industries Ltd. Gram-positive Bacterial Infections Introduction

11.9.4 Sun Pharmaceutical Industries Ltd. Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.9.5 Sun Pharmaceutical Industries Ltd. Recent Development

11.10 Cipla

11.10.1 Cipla Company Detail

11.10.2 Cipla Business Overview

11.10.3 Cipla Gram-positive Bacterial Infections Introduction

11.10.4 Cipla Revenue in Gram-positive Bacterial Infections Business (2018-2023)

11.10.5 Cipla Recent Development

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.2 Data Source

13.2 Disclaimer

13.3 Author Details

List of Tables

    Table 1. Global Gram-positive Bacterial Infections Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029

    Table 2. Key Players of B-Lactam Antimicrobials

    Table 3. Key Players of Fluoroquinolones

    Table 4. Key Players of Penicillin

    Table 5. Key Players of Cephalosporins

    Table 6. Key Players of RNA Immunoprecipitation (RIP)

    Table 7. Key Players of Vaccine

    Table 8. Key Players of Other

    Table 9. Global Gram-positive Bacterial Infections Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029

    Table 10. Global Gram-positive Bacterial Infections Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 11. Global Gram-positive Bacterial Infections Market Size by Region (2018-2023) & (US$ Million)

    Table 12. Global Gram-positive Bacterial Infections Market Share by Region (2018-2023)

    Table 13. Global Gram-positive Bacterial Infections Forecasted Market Size by Region (2024-2029) & (US$ Million)

    Table 14. Global Gram-positive Bacterial Infections Market Share by Region (2024-2029)

    Table 15. Gram-positive Bacterial Infections Market Trends

    Table 16. Gram-positive Bacterial Infections Market Drivers

    Table 17. Gram-positive Bacterial Infections Market Challenges

    Table 18. Gram-positive Bacterial Infections Market Restraints

    Table 19. Global Gram-positive Bacterial Infections Revenue by Players (2018-2023) & (US$ Million)

    Table 20. Global Gram-positive Bacterial Infections Market Share by Players (2018-2023)

    Table 21. Global Top Gram-positive Bacterial Infections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-positive Bacterial Infections as of 2022)

    Table 22. Ranking of Global Top Gram-positive Bacterial Infections Companies by Revenue (US$ Million) in 2022

    Table 23. Global 5 Largest Players Market Share by Gram-positive Bacterial Infections Revenue (CR5 and HHI) & (2018-2023)

    Table 24. Key Players Headquarters and Area Served

    Table 25. Key Players Gram-positive Bacterial Infections Product Solution and Service

    Table 26. Date of Enter into Gram-positive Bacterial Infections Market

    Table 27. Mergers & Acquisitions, Expansion Plans

    Table 28. Global Gram-positive Bacterial Infections Market Size by Type (2018-2023) & (US$ Million)

    Table 29. Global Gram-positive Bacterial Infections Revenue Market Share by Type (2018-2023)

    Table 30. Global Gram-positive Bacterial Infections Forecasted Market Size by Type (2024-2029) & (US$ Million)

    Table 31. Global Gram-positive Bacterial Infections Revenue Market Share by Type (2024-2029)

    Table 32. Global Gram-positive Bacterial Infections Market Size by Application (2018-2023) & (US$ Million)

    Table 33. Global Gram-positive Bacterial Infections Revenue Market Share by Application (2018-2023)

    Table 34. Global Gram-positive Bacterial Infections Forecasted Market Size by Application (2024-2029) & (US$ Million)

    Table 35. Global Gram-positive Bacterial Infections Revenue Market Share by Application (2024-2029)

    Table 36. North America Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 37. North America Gram-positive Bacterial Infections Market Size by Country (2018-2023) & (US$ Million)

    Table 38. North America Gram-positive Bacterial Infections Market Size by Country (2024-2029) & (US$ Million)

    Table 39. Europe Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 40. Europe Gram-positive Bacterial Infections Market Size by Country (2018-2023) & (US$ Million)

    Table 41. Europe Gram-positive Bacterial Infections Market Size by Country (2024-2029) & (US$ Million)

    Table 42. Asia-Pacific Gram-positive Bacterial Infections Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 43. Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2018-2023) & (US$ Million)

    Table 44. Asia-Pacific Gram-positive Bacterial Infections Market Size by Region (2024-2029) & (US$ Million)

    Table 45. Latin America Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 46. Latin America Gram-positive Bacterial Infections Market Size by Country (2018-2023) & (US$ Million)

    Table 47. Latin America Gram-positive Bacterial Infections Market Size by Country (2024-2029) & (US$ Million)

    Table 48. Middle East & Africa Gram-positive Bacterial Infections Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029

    Table 49. Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2018-2023) & (US$ Million)

    Table 50. Middle East & Africa Gram-positive Bacterial Infections Market Size by Country (2024-2029) & (US$ Million)

    Table 51. GlaxoSmithKline Company Detail

    Table 52. GlaxoSmithKline Business Overview

    Table 53. GlaxoSmithKline Gram-positive Bacterial Infections Product

    Table 54. GlaxoSmithKline Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 55. GlaxoSmithKline Recent Development

    Table 56. Johnson & Johnson Inc. Company Detail

    Table 57. Johnson & Johnson Inc. Business Overview

    Table 58. Johnson & Johnson Inc. Gram-positive Bacterial Infections Product

    Table 59. Johnson & Johnson Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 60. Johnson & Johnson Inc. Recent Development

    Table 61. Merck & Co. Inc. Company Detail

    Table 62. Merck & Co. Inc. Business Overview

    Table 63. Merck & Co. Inc. Gram-positive Bacterial Infections Product

    Table 64. Merck & Co. Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 65. Merck & Co. Inc. Recent Development

    Table 66. Pfizer Inc. Company Detail

    Table 67. Pfizer Inc. Business Overview

    Table 68. Pfizer Inc. Gram-positive Bacterial Infections Product

    Table 69. Pfizer Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 70. Pfizer Inc. Recent Development

    Table 71. AstraZeneca Company Detail

    Table 72. AstraZeneca Business Overview

    Table 73. AstraZeneca Gram-positive Bacterial Infections Product

    Table 74. AstraZeneca Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 75. AstraZeneca Recent Development

    Table 76. Astellas Pharma Inc. Company Detail

    Table 77. Astellas Pharma Inc. Business Overview

    Table 78. Astellas Pharma Inc. Gram-positive Bacterial Infections Product

    Table 79. Astellas Pharma Inc. Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 80. Astellas Pharma Inc. Recent Development

    Table 81. Novartis AG Company Detail

    Table 82. Novartis AG Business Overview

    Table 83. Novartis AG Gram-positive Bacterial Infections Product

    Table 84. Novartis AG Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 85. Novartis AG Recent Development

    Table 86. Sanofi SA Company Detail

    Table 87. Sanofi SA Business Overview

    Table 88. Sanofi SA Gram-positive Bacterial Infections Product

    Table 89. Sanofi SA Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 90. Sanofi SA Recent Development

    Table 91. Sun Pharmaceutical Industries Ltd. Company Detail

    Table 92. Sun Pharmaceutical Industries Ltd. Business Overview

    Table 93. Sun Pharmaceutical Industries Ltd. Gram-positive Bacterial Infections Product

    Table 94. Sun Pharmaceutical Industries Ltd. Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 95. Sun Pharmaceutical Industries Ltd. Recent Development

    Table 96. Cipla Company Detail

    Table 97. Cipla Business Overview

    Table 98. Cipla Gram-positive Bacterial Infections Product

    Table 99. Cipla Revenue in Gram-positive Bacterial Infections Business (2018-2023) & (US$ Million)

    Table 100. Cipla Recent Development

    Table 101. Research Programs/Design for This Report

    Table 102. Key Data Information from Secondary Sources

    Table 103. Key Data Information from Primary Sources

List of Figures

    Figure 1. Global Gram-positive Bacterial Infections Market Size Comparison by Type (2023-2029) & (US$ Million)

    Figure 2. Global Gram-positive Bacterial Infections Market Share by Type: 2022 VS 2029

    Figure 3. B-Lactam Antimicrobials Features

    Figure 4. Fluoroquinolones Features

    Figure 5. Penicillin Features

    Figure 6. Cephalosporins Features

    Figure 7. RNA Immunoprecipitation (RIP) Features

    Figure 8. Vaccine Features

    Figure 9. Other Features

    Figure 10. Global Gram-positive Bacterial Infections Market Size Comparison by Application (2023-2029) & (US$ Million)

    Figure 11. Global Gram-positive Bacterial Infections Market Share by Application: 2022 VS 2029

    Figure 12. Hospital Case Studies

    Figure 13. Clinic Case Studies

    Figure 14. Other Case Studies

    Figure 15. Gram-positive Bacterial Infections Report Years Considered

    Figure 16. Global Gram-positive Bacterial Infections Market Size (US$ Million), Year-over-Year: 2018-2029

    Figure 17. Global Gram-positive Bacterial Infections Market Size, (US$ Million), 2018 VS 2022 VS 2029

    Figure 18. Global Gram-positive Bacterial Infections Market Share by Region: 2022 VS 2029

    Figure 19. Global Gram-positive Bacterial Infections Market Share by Players in 2022

    Figure 20. Global Top Gram-positive Bacterial Infections Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gram-positive Bacterial Infections as of 2022)

    Figure 21. The Top 10 and 5 Players Market Share by Gram-positive Bacterial Infections Revenue in 2022

    Figure 22. North America Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 23. North America Gram-positive Bacterial Infections Market Share by Country (2018-2029)

    Figure 24. United States Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 25. Canada Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 26. Europe Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 27. Europe Gram-positive Bacterial Infections Market Share by Country (2018-2029)

    Figure 28. Germany Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 29. France Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 30. U.K. Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 31. Italy Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 32. Russia Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 33. Nordic Countries Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 34. Asia-Pacific Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 35. Asia-Pacific Gram-positive Bacterial Infections Market Share by Region (2018-2029)

    Figure 36. China Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 37. Japan Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 38. South Korea Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 39. Southeast Asia Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 40. India Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 41. Australia Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 42. Latin America Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 43. Latin America Gram-positive Bacterial Infections Market Share by Country (2018-2029)

    Figure 44. Mexico Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 45. Brazil Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 46. Middle East & Africa Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 47. Middle East & Africa Gram-positive Bacterial Infections Market Share by Country (2018-2029)

    Figure 48. Turkey Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 49. Saudi Arabia Gram-positive Bacterial Infections Market Size YoY Growth (2018-2029) & (US$ Million)

    Figure 50. GlaxoSmithKline Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 51. Johnson & Johnson Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 52. Merck & Co. Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 53. Pfizer Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 54. AstraZeneca Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 55. Astellas Pharma Inc. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 56. Novartis AG Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 57. Sanofi SA Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 58. Sun Pharmaceutical Industries Ltd. Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 59. Cipla Revenue Growth Rate in Gram-positive Bacterial Infections Business (2018-2023)

    Figure 60. Bottom-up and Top-down Approaches for This Report

    Figure 61. Data Triangulation

    Figure 62. Key Executives Interviewed